Skip to content
Hugin
An empty clinic interior with blue examination couches and medical equipment visible through two doorways.

Hugin News

Medicare Part D generally did not cover over-the-counter naloxone spray in 2025, GAO finds

1 min read

Original editorial artwork from the Hugin archive; symbolic illustration, not a depiction of the subject.

This record was prepared on the date shown and recovered after a publishing interruption.

Medicare Part D plans generally did not cover over-the-counter naloxone nasal spray in 2025, while Medicaid covered it for enrollees in 2024, according to a November 9 Government Accountability Office report. The years differ, and all enrollees in the programs had coverage for some form of naloxone in the years reviewed.

healthmedicaremedicaidnaloxonedrug-coverage
source receipt
1
source host
1
read time
1min
primary source
Linked

Medicare Part D plans generally did not cover over-the-counter naloxone nasal spray in 2025, while Medicaid covered the spray for enrollees in 2024, according to a Government Accountability Office report released November 9.

Those findings use different years. GAO found that all Medicare Part D and Medicaid enrollees had coverage for some form of naloxone in the respective years it reviewed.

What was covered

Naloxone reverses opioid overdoses and comes in injectable and nasal spray forms, GAO says. Low-dose nasal sprays have been available over the counter since 2023. The report also examines nalmefene, another overdose reversal medication that GAO describes as newer and longer acting.

GAO says both Medicare and Medicaid covered naloxone injectables in the years reviewed. Coverage of nalmefene was less common than coverage of naloxone. For the state Medicaid analysis, GAO counted a state as having coverage when the medications were used under the program; other states could have coverage without utilization.

The analysis used Medicare Part D data for 2025 and Medicaid drug reimbursement data for 2024 from all 50 states and the District of Columbia. They were the most recent data available to GAO for its analysis, and they do not establish what an individual plan covers now.

Costs varied by formulation

For Medicare Part D, GAO says out-of-pocket costs varied by formulation and whether a product was generic or branded. Median copays for generic naloxone injections ranged from $3 to $10. Median coinsurance for branded high-dose naloxone and nalmefene nasal sprays ranged from 25 percent to 35 percent.

GAO examined Medicaid copays in four selected states: two had none, and the other two had copays below $5. That selection does not represent every state's costs.

Source links